Sponsor & Developer Portfolio

Pfizer

Clinical development pipeline, platform architecture, and registered trial tracking for Pfizer vaccine candidates.

23
Candidates
12
Target Diseases
28
Linked Studies

Development Phase Distribution

Discontinued / Inactive: 10 Phase 3 Clinical Trial: 8 Approved / Licensed: 2 Phase 2 Clinical Trial: 2 Phase 1 Clinical Trial: 1

Platform Technologies

Biological (unspecified platform): 15 See FDA product page / label: 2 Conjugate vaccine: 2 mRNA: 2 Protein subunit (OspA): 1 DNA: 1

Target Pathogens & Indications

Alzheimer Disease Alzheimer's Disease Clostridoides Difficile Associated Disease HIV Influenza Lyme disease Meningococcal disease Pneumococcal disease Prostatic Neoplasms RSV Staphylococcal Vaccine Varicella / Zoster

Vaccine Pipeline Candidates (23)

Detailed candidate profiles, clinical phases, target indications, and anticipated milestones.

Approved / Licensed fda-abrysvo

ABRYSVO

Target: RSV

Platform: See FDA product page / label

Key Milestone: US-licensed — see product label / ACIP for use; further supplements may expand indication
Approved / Licensed fda-penbraya

PENBRAYA

Target: Meningococcal disease

Platform: See FDA product page / label

Key Milestone: US-licensed — see product label / ACIP for use; further supplements may expand indication
Discontinued / Inactive ctgov-acc-001-pfizer

ACC-001

Target: Alzheimer's Disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2013-12 (registry estimate)
Discontinued / Inactive ctgov-acc-001-qs21-3mcg-pfizer

ACC-001+ QS21 (3mcg)

Target: Alzheimer Disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2013-12 (registry estimate)
Discontinued / Inactive ctgov-candidate-1-pf-07915234-vzv-modrna-powder-for-suspension-for-inj

Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection

Target: Varicella / Zoster

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2025-09-23 (registry estimate)
Discontinued / Inactive ctgov-hiv-1-gag-dna-formulated-with-bupivacaine-wyeth-is-now-a-wholly-

IL-15 DNA (formulated with bupivacaine)

Target: HIV

Platform: DNA

Key Milestone: See linked ClinicalTrials.gov records for primary completion dates
Discontinued / Inactive ctgov-menabcwy-pfizer

MenABCWY (Pfizer)

Target: Meningococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2022-09-15 (registry estimate)
Discontinued / Inactive ctgov-pf-06755992-pfizer

PF-06755992

Target: Prostatic Neoplasms

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2021-02-23 (registry estimate)
Discontinued / Inactive ctgov-multivalent-pfizer

Pfizer multivalent pneumococcal conjugate vaccine (unnamed)

Target: Pneumococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2020-11-05 (registry estimate)
Discontinued / Inactive ctgov-pneumo-23-wyeth-is-now-a-wholly-owned-subsidiary-of-pfizer

Pneumo 23

Target: Pneumococcal disease

Platform: Conjugate vaccine

Key Milestone: See linked ClinicalTrials.gov records for primary completion dates
Discontinued / Inactive ctgov-staphylococcus-aureus-4-antigen-sa4ag-vaccine-pfizer

Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine

Target: Staphylococcal Vaccine

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2019-06-26 (registry estimate)
Discontinued / Inactive ctgov-meningococcal-b-rlp2086-vaccine-pfizer

meningococcal B rLP2086 vaccine

Target: Meningococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2009-06 (registry estimate)
Phase 1 Clinical Trial ctgov-pg4-vaccine-in-buffer-1-with-low-dose-pa-001-pfizer

PG4 in Buffer 1 with low dose PA-002

Target: Pneumococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2027-10-21 (registry estimate)
Phase 2 Clinical Trial ctgov-c-difficile-vaccine-previously-studied-formulation-pfizer

C. difficile vaccine formulation 1.

Target: Clostridoides Difficile Associated Disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2031-06-19 (registry estimate)
Phase 2 Clinical Trial ctgov-vaccine-candidate-1-pfizer

Pfizer mRNA influenza vaccine candidates (#1-#6, unnamed)

Target: Influenza

Platform: mRNA

Key Milestone: Primary completion (most advanced trial): 2027-06-22 (registry estimate)
Phase 3 Clinical Trial ctgov-20vpnc-pfizer

20vPnC

Target: Pneumococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2028-11-30 (registry estimate)
Phase 3 Clinical Trial ctgov-c-difficile-vaccine-pfizer

C.difficile vaccine

Target: Clostridoides Difficile Associated Disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2028-12-11 (registry estimate)
Phase 3 Clinical Trial ctgov-pg4-pfizer

PG4

Target: Pneumococcal disease

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2029-06-05 (registry estimate)
Phase 3 Clinical Trial ctgov-pg4-multivalent-vaccine-pfizer

PG4 Multivalent Vaccine

Target: Pneumococcal disease

Platform: Conjugate vaccine

Key Milestone: Primary completion (most advanced trial): 2027-06-07 (registry estimate)
Phase 3 Clinical Trial ctgov-rsvpref-pfizer

RSVpreF

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2027-01-18 (registry estimate)
Phase 3 Clinical Trial ctgov-rsvpref-regimen-a-pfizer

RSVpreF (Regimen A)

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2029-02-07 (registry estimate)
Phase 3 Clinical Trial ctgov-rsvpref-vaccine-pfizer

RSVpreF Vaccine

Target: RSV

Platform: Biological (unspecified platform)

Key Milestone: Primary completion (most advanced trial): 2028-02-02 (registry estimate)
Phase 3 Clinical Trial vla15

VLA15

Target: Lyme disease

Platform: Protein subunit (OspA)

Key Milestone: VALOR Phase 3 field efficacy results (company: H1 2026); BLA/MAA planned if positive

Explore Other Vaccine Developers & Sponsors

Compare pipeline volume, phase progression, and modalities across global biopharmaceutical manufacturers.

View All Vaccine Developers →